HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Gábor Szabó Matthias Karck Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Szabó, G. Articles by van de Locht, A. Search for Related Content PubMed PubMed Citation Articles by Szabó, G. Articles by van de Locht, A. Related Collections Cardiac - pharmacology Extracorporeal circulation

J Thorac Cardiovasc Surg 2010;139:181-188
© 2010 The American Association for Thoracic Surgery

Evolving Technology/Basic Science

Effects of novel synthetic serine protease inhibitors on postoperative blood loss, coagulation parameters, and vascular relaxation after cardiac surgery

^a Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany
^b Department of Cardiology, Angiology, and Pulmonology, University of Heidelberg, Heidelberg, Germany
^c Department of Cardiovascular Surgery, Semmelweis University Medical School, Budapest, Hungary
^d Curacyte Discovery GmbH, Leipzig, Germany

Received for publication May 8, 2008; revisions received August 9, 2009; accepted for publication September 7, 2009.

^_* Address for reprints: Gábor Szabó, MD, PhD, Department of Cardiac Surgery, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany. (Email: gabor.szabo{at}urz.uni-heidelberg.de).

Objective: Although aprotinin has been widely used to reduce perioperative blood loss after cardiopulmonary bypass, recent concerns have led to its withdrawal. This study investigated effects of the novel synthetic serine protease inhibitors CU-2010 and CU-2020 on blood loss, coagulation parameters, and coronary relaxation in a canine model.

Methods: Thirty-seven dogs were divided into 5 groups: control (n = 5), aprotinin (n = 8, Hammersmith scheme of intravenous bolus, prime, and continuous infusion), Hammersmith CU-2010 (n = 8, 1.6 mg/kg Hammersmith scheme), continuous CU-2010 (n = 8, 1.6 mg/kg continuous infusion), and CU-2020 (n = 8, 8.9 mg/kg Hammersmith scheme). All animals underwent 90-minute cardiopulmonary bypass. End points were blood loss during first 2 hours after protamine and activated clotting, partial thromboplastin, and prothrombin times. At end of experiments, coronary rings were removed for in vitro testing of relaxation to acetylcholine and sodium nitroprusside.

Results: Hammersmith and continuous CU-2010, CU-2020, and aprotinin groups all had reduced blood loss (43 ± 4, 43 ± 8, 52 ± 7, 61 ± 7, respectively, vs control 149 ± 24 mL, P < .05). After protamine, activated clotting time and partial thromboplastin time normalized in control, aprotinin, and Hammersmith CU-2010 groups but remained elevated in continuous CU-2010 and CU-2020 groups. Prothrombin time and vascular relaxation did not differ between groups.

Conclusions: CU-2010 and CU-2020 significantly reduced blood loss after cardiac surgery, with prolonged partial thromboplastin and activated clotting times, demonstrating improved antithrombotic profile. Neither aprotinin nor the novel serine protease inhibitors influenced vascular relaxation.